Specifically, exosomes secreted by breast cancer patients’ serum, carrying HER2 antigen that is the target of Trastuzumab, contribute to drug sequestration, reducing therapeutic efficacy [18]. The gene discussed is ERBB2; the disease is breast carcinoma.